101 – 200 of 302
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia
(
- Contribution to journal › Article
-
Mark
Diabetes Mellitus and Elevated Copeptin Levels in Middle Age Predict Low Cognitive Speed after Long-Term Follow-Up.
(
- Contribution to journal › Article
-
Mark
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy
(
- Contribution to journal › Article
-
Mark
Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
(
- Contribution to journal › Article
-
Mark
Complement Gene Single Nucleotide Polymorphisms and Biomarker Endophenotypes of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Binary classification of F-18-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI
(
- Contribution to journal › Article
-
Mark
Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia
(
- Contribution to journal › Article
-
Mark
Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters.
(
- Contribution to journal › Article
-
Mark
The Association Between APOE epsilon 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study
(
- Contribution to journal › Article
-
Mark
Multidisciplinary intervention reducing readmissions in medical inpatients: a prospective, non-randomized study
(
- Contribution to journal › Article
-
Mark
Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Functional Mannose-Binding Lectin Haplotype Variants are Associated with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study
(
- Contribution to journal › Article
-
Mark
Living Alone in Alzheimer’s Disease—The Influence of Functional Impairment.
2013) 6th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster
-
Mark
Three-year outcome of rivastigmine treatment in Alzheimer's disease in a routine clinical setting.
2013) 11th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2013)(
- Contribution to conference › Poster
-
Mark
Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment
(
- Contribution to journal › Article
- 2012
-
Mark
A longitudinal study of physical function in patients with early-onset dementia
(
- Contribution to journal › Article
-
Mark
A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Age and diagnostic performance of Alzheimer disease CSF biomarkers
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
No diagnostic value of plasma clusterin in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study.
(
- Contribution to journal › Article
-
Mark
Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
The impact of autonomic dysfunction on survival in patients with dementia with lewy bodies and Parkinson's disease with dementia.
(
- Contribution to journal › Article
-
Mark
Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease.
(
- Contribution to journal › Article
-
Mark
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort
(
- Contribution to journal › Article
-
Mark
Cognitive impairment is undetected in medical inpatients: a study of mortality and recognition amongst healthcare professionals
(
- Contribution to journal › Article
-
Mark
Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Profiles of Amyloid beta-Related Biomarkers in Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid
(
- Contribution to journal › Article
-
Mark
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent
(
- Contribution to journal › Article
-
Mark
Safety, tolerability, and antibody response of active A beta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
(
- Contribution to journal › Article
-
Mark
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
(
- Contribution to journal › Article
-
Mark
Amyloid-beta Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Altered CSF Orexin and α-Synuclein Levels in Dementia Patients.
(
- Contribution to journal › Article
-
Mark
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
(
- Contribution to journal › Article
-
Mark
Injury markers predict time to dementia in subjects with MCI and amyloid pathology.
2012) In Neurology(
- Contribution to journal › Article
-
Mark
Risk factors for community-based home help services among patients with Alzheimer’s disease.
2012) 21st Nordic Congress of Gerontology(
- Contribution to conference › Poster
-
Mark
A new automated method for analysis of rCBF-SPECT images based on the active-shape algorithm: normal values.
(
- Contribution to journal › Article
-
Mark
Alzheimer’s disease with normal CSF biomarkers.
2012) 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly.
(
- Contribution to journal › Article
-
Mark
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
(
- Contribution to journal › Article
- 2011
-
Mark
Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Ubiquitin Carboxyl-Terminal Esterase L1 (UCHL1) S18Y Polymorphism In Patients With Cataracts
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid/plasma quotients of essential and non-essential metals in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
CSF amyloid beta 38 as a novel diagnostic marker for dementia with Lewy bodies
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment.
(
- Contribution to journal › Article
-
Mark
Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinson's Disease Dementia.
(
- Contribution to journal › Article
-
Mark
Regional Differences in Effects of APOE epsilon 4 on Cognitive Impairment in Non-Demented Subjects
(
- Contribution to journal › Article
-
Mark
Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Prediction of Alzheimer's Disease Using Midregional Proadrenomedullin and Midregional Proatrial Natriuretic Peptide: A Retrospective Analysis of 134 Patients With Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
No Association of LOXL1 Gene Polymorphisms with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Differences in Survival between Patients with Dementia with Lewy Bodies and Patients with Alzheimer's Disease - Measured from a Fixed Cognitive Level.
(
- Contribution to journal › Article
-
Mark
The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.
(
- Contribution to journal › Article
-
Mark
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.
(
- Contribution to journal › Article
-
Mark
Predictors of long-term cognitive outcome in Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
The long-term cognitive outcomes of Alzheimer’s disease — influence of APOE genotype, NSAID therapy, and cholinesterase inhibitor treatment.
2011) 10th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2011)(
- Contribution to conference › Poster
- 2010
-
Mark
Association of the RAGE G82S polymorphism with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
A beta 40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
BACE1 gene variants do not influence BACE1 activity, levels of APP or A beta isoforms in CSF in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
(
- Contribution to journal › Article
-
Mark
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cystatin C Levels are Positively Correlated with both A beta(42) and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls
(
- Contribution to journal › Article
-
Mark
alpha-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies
(
- Contribution to journal › Article
-
Mark
Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls
(
- Contribution to journal › Article
-
Mark
Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract
(
- Contribution to journal › Article
-
Mark
No Association of VEGF Polymorphims with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Evaluation of plasma A beta(40) and A beta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment.
(
- Contribution to journal › Article
-
Mark
Kinesin Light Chain 1 Gene Haplotypes in Three Conformational Diseases
(
- Contribution to journal › Article
-
Mark
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.
(
- Contribution to journal › Article
-
Mark
CSF biomarkers predict a more malignant outcome in Alzheimer disease.
(
- Contribution to journal › Article
-
Mark
Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years.
(
- Contribution to journal › Article
-
Mark
Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
(
- Contribution to journal › Article
-
Mark
Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years.
(
- Contribution to journal › Article
-
Mark
Plasma concentration of galantamine - influence of dose and body mass index in Alzheimer’s disease.
2010) 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.
(
- Contribution to journal › Article
-
Mark
The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia.
(
- Contribution to journal › Article
-
Mark
Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
F-18-Flutemetamol Amyloid Imaging in Alzheimer Disease and Mild Cognitive Impairment A Phase 2 Trial
(
- Contribution to journal › Article
-
Mark
Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients
(
- Contribution to journal › Article
- 2009
-
Mark
Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
The PPAR-alpha gene in Alzheimer's disease: Lack of replication of earlier association
(
- Contribution to journal › Article
-
Mark
Medial Temporal Lobe Atrophy Increases the Specificity of Cerebrospinal Fluid Biomarkers in Alzheimer Disease with Minor Cerebrovascular Changes.
(
- Contribution to journal › Article
-
Mark
Long-term rivastigmine treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk
(
- Contribution to journal › Article
-
Mark
Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
2009) 13th Congress of the European-Federation-of-Neurological-Societies In European Journal of Neurology 16(Suppl 3). p.337-337(
- Contribution to journal › Published meeting abstract
-
Mark
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil
(
- Contribution to journal › Article